Eruption cyst formation associated with cyclosporin A. A case report

Department of Periodontology, University of Muenster, Germany.
Journal Of Clinical Periodontology (Impact Factor: 3.61). 06/2003; 30(5):462-6. DOI: 10.1034/j.1600-051X.2003.02028.x
Source: PubMed

ABSTRACT Cyclosporin A (CyA) is a potent immunomodulatory agent with a wide range of applications. Despite its therapeutic value, multiple adverse effects of CyA have been identified. This case report describes eruption cyst formation as a possible adverse effect of CyA administration during tooth eruption in a boy treated with CyA as a consequence of a cardiac transplantation. The clinical diagnosis of eruption cyst was confirmed by histopathological examination.
The periodontal treatment consisted of supragingival and subgingival scaling, followed by surgical removal of the tissues overlying the crowns of the teeth associated with eruption cysts, and flap surgery in the region of gingival overgrowth. The patient was then placed on quarterly periodontal supportive therapy and his immunosuppressive medication was switched from CyA to tacrolimus.
Twenty months after therapy, neither new cyst formation nor recurrence of gingival overgrowth was registered.
Formation of an eruption cyst may be an adverse effect of CyA in children with erupting teeth.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Cyclosporin is a potent immunosuppressive drug and is frequently used in the therapy of autoimmune diseases, including systemic lupus erythematosus (SLE). Few large studies have been performed using this drug in SLE patients. However, small uncontrolled studies of patients with SLE have shown favourable results with a significant improvement in disease activity, a fall in anti ds DNA titres and proteinuria and an improvement in complement levels, leucopaenia and thrombocytopaenia. Interestingly, a consistent reduction in corticosteroid dosage often by as much as 50% is seen. Toxicity, especially with hypertension and renal impairment, occurs but usually reverses on dose reduction or the addition of an anti-hypertensive agent and is minimised by adherence to the strict monitoring guidelines. Large multi-centre randomised-controlled trials of the use of cyclosporin in SLE patients are underway and the results are eagerly awaited.
    Lupus 02/2001; 10(3):165-70. DOI:10.1191/096120301672970034 · 2.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In the Medical Clinic at the University of Basle, the immunosuppressive drug cyclosporin-A has been employed recently for kidney transplant patients. A side effect of this drug appears to be pronounced gingival enlargement. This report documents 3 such cases, with a discussion of etiology and possible treatment modalities
    Journal Of Clinical Periodontology 06/1983; 10(3):237-46. DOI:10.1111/j.1600-051X.1983.tb01272.x · 3.61 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cyclosporin A (CsA), a cyclic endecapeptide, is a T cell-specific immunosuppressant and is successfully used in the field of organ transplantation. Another T cell-specific immunosuppressant, FK506, a more recently discovered macrolide antibiotic, is effective against graft rejection at much lower doses than CsA. Although totally different in structure, both compounds inhibit T cell activation by interfering with the production of interleukin-2 (IL-2) by inhibiting IL-2 gene expression, probably through the inhibition of calcineurin, a Ca2+/calmodulin-dependent phosphatase. Clinical studies have revealed that FK506 induces a variety of side effects in common with CsA. One of the most common side effects of CsA is hypertrichosis. The hair growth stimulating effect of CsA is observed not only in normal but also in pathological conditions of hair growth, i.e. in patients with alopecia areata and also in some patients with male-pattern alopecia. Although hypertrichosis is induced by both topical and oral administration of CsA, there has been no report showing that FK506 induces hypertrichosis. Recently we have found that topical application of FK506 to skins of mice, rats and hamsters markedly stimulates hair growth. This hair growth stimulating effect of FK506 is observed when applied topically but not by oral administration, even with a dose which causes marked immunosuppression. The hair growth stimulating effect of FK506 in normal animals may apparently be unrelated to its immunosuppressive effect. In vitro studies revealed that FK506 directly stimulates hair follicles. Mechanisms of hair growth stimulating effects of FK506 and CsA remain to be elucidated.(ABSTRACT TRUNCATED AT 250 WORDS)
    Journal of Dermatological Science 08/1994; 7 Suppl(Suppl):S47-54. DOI:10.1016/0923-1811(94)90035-3 · 3.34 Impact Factor
Show more